Biomarkers for acute ischemic stroke
Authors/year | Study design | Population | N | Bio-marker | Sample source | Findings |
---|---|---|---|---|---|---|
Markers of CNS origin | ||||||
Kazmierski, 2012 | Pro | AIS | 458 | s100β, OCLN, CLDN5, ZO1 | Serum | Patients with clinical deterioration due to hemorrhagic transformation had higher s100β, OCLN, and CLDN/ZO1 ratio |
Foerch, 2004 | Pro | AIS within 6 h of onset with proximal MCA occlusion | 51 | s100β | Serum | Mean s100β were higher in patients with malignant cerebral edema defined s100β > 1.03 μg/L at 24 h post AIS predicted malignant infarction (94 % sensitivity; 83 % specificity) |
Missler, 1997 | Pro | AIS diagnosed by CT | 44 | s100β, NSE | Serum | s100β correlated with infarct volume and with 6 month outcome NSE correlated with infarct volume but not with clinical outcome Did not adjust for stroke subtype or tPA treatment |
Foerch, 2005 | Pro | AIS within 6 h of onset | 39 | s100β | Serum | s100β at 48–72 h post AIS correlated with 6 month outcome and with infarct volume s100β ≤ 0.37 μg/L at 48 h post stroke predicted functional independence at 6 months (87 % sensitivity; 78 % specificity) |
Hermann, 2000 | Pro | Anterior circulation AIS | 32 | s100β, GFAP | Serum | s100β and GFAP correlated with total infarct volume and neurologic status at hospital discharge Did not adjust for stroke subtype or tPA treatment |
Foerch, 2003 | Pro | AIS ≤ 5 h of onset with M1 occlusion | 23 | s100β | Serum | s100β < 0.4 μg/L at 48–96 h post-AIS predicted MCA recanalization within 6 h (86 % sensitivity; 100 % specificity) |
Biomarkers of inflammation and blood brain barrier | ||||||
Den Hergot, 2009 | RCT | AIS ≤ 12 h onset, no liver disease, prior mRS < 2 | 561 | CRP | Serum | From RCT for paracetamol for ischemic stroke CRP measured within 12 h of stroke onset CRP > 7 mg/L is associated with poor outcome (OR 1.6 [1.1–2.4]) and death (OR 1.7 [1.0–2.9]) |
Idicula, 2009 | Nested Pro | AIS ≤ 24 h onset | 498 | CRP | Serum | CRP > 10 mg/L is independently associated with high NIHSS and high long term mortality at 2.5 years |
Montaner, 2006 | Pro | AIS in MCA territory treated with IV tPA within 3 h; exclude inflammatory disease or infection | 143 | CRP | Serum | CRP measured before tPA administration CRP was higher in those who died after thrombolysis compared with survivors (0.85 vs. 0.53 mg/dL) CRP is independently associated with mortality at 3 months (OR 8.51 [2.16–33.5]) |
Winbeck, 2002 | Pro | AIS B 12 h onset, NOT treated with IV tPA | 127 | CRP | Serum | CRP > 0.86 mg/dL 24 h and at 48 h post-stroke are associated with death and lower likelihood of event-free survival at 1 year |
Topakian, 2008 | Pro | AIS in MCA territory treated with IV tPA ≤ 6 h of onset, exclude CRP > 6 mg/dL | 111 | CRP | Serum | CRP measured before tPA administration CRP level was not associated with NIHSS within 24 h or outcome at 3 months |
Shantikumar, 2009 | Pro | AIS surviving >30 days | 394 | CRP | Serum | CRP higher in subject who died compared to survivors CRP is independently predictive of mortality after adjusting for conventional risk factors |
Elkind, 2006 | Retro | Age > 40, reside in northern Manhattan > 3 months | 467 | hs-CRP | Serum | Highest quartile of hs-CRP is associated with increased risk of stroke recurrence (HR = 2.08 [1.04–4.18]) and with combined outcome of stroke, MI, or vascular death (HR = 1.86 [1.01–3.42]) |
Huang, 2012 | Retro | Age > 40, reside in northern Manhattan > 3 months | 741 | hs-CRP | Serum | hs-CRP > 3 mg/L was associated with higher mortality at 3 months and all-cause mortality (HR = 6.48 [1.41–29.8]) |
Castellanos, 2003 | Pro | Hemispheric AIS within 7.8 ± 4.5 h of onset | 250 | MMP9 | Plasma | MMP9 ≥ 140 μg/L predicted hemorrhagic transformation (61 % PPV; 97 % NPV) |
Castellanos, 2007 | Pro | AIS ≤ 3 h treated with IV tPA | 134 | c-Fn, MMP9 | Serum | MMP9 ≥ 140 μg/L predicted hemorrhagic transformation (92 % sensitivity; 74 % specificity; 26 % PPV; 99 % NPV) c-Fn ≥ 3.6 μg/mL predicted hemorrhagic transformation (100 % sensitivity; 60 % specificity; 20 % PPV; 100 % NPV) |
Moldes, 2008 | Pro | AIS treated with IV tPA | 134 | ET-1, MMP9, c-Fn | Serum | ET-1, MMP9, and c-Fn measured upon admission before tPA bolus. ET-1 and c-Fn significantly higher in those with severe cerebral edema ET-1 > 5.5 fmol/mL before tPA was independently associated with severe brain edema in multivariate analysis |
Serena, 2005 | Case control | Malignant MCA infarction, <70 years | 40 AIS, 35 CTRL | c-Fn, MMP9 | Plasma | c-Fn and MMP-9 were significantly higher in patients with malignant MCA infarcts c-Fn > 16.6 μg/mL predicted malignant infarction (90 % sensitivity; 100 % specificity; 89 % NPV; 100 % PPV) |
Montaner, 2003 | Pro | AIS in MCA territory treated with IV tPA within 3 h | 41 | MMP9 | Plasma | Higher baseline (pre-tPA) MMP9 was associated with hemorrhagic transformation in dose-dependent fashion MMP9 was predictive of hemorrhagic transformation in multivariate model (OR 9.62) |
Montaner, 2001 | Pro | Cardioembolic AIS in MCA territory | 39 | MMP9 | Plasma | Elevated baseline MMP9 was associated with late hemorrhagic transformation in multivariate regression (OR 9) |
Castellanos, 2004 | Pro | AIS treated with IV tPA by ECASS II criteria | 87 | c-Fn | Plasma | c-Fn was independently associated with hemorrhagic transformation in multivariate analysis (OR 2.1). 71 of the patients were treated within 3 h of AIS onset. Similar results were found in these patients |
Guo, 2011 | Pro | First onset AIS | 172 AIS, 50 CTRL | pGSN | Plasma | Samples from first 24 h of stroke onset obtained. pGSN decreased in AIS compared to controls pGSN was independent predictor for 1-year mortality pGSN > 52 mg/L predicted 1-year mortality (73 % sensitivity; 65.2 % specificity) |
Yin, 2013 | Pro | AIS | 186 AIS, 100 CTRL | Visfatin | Plasma | Visfatin was higher in AIS than in controls Visfatin was independent predictor of 6-month clinical outcome Adding visfatin did not improve predictive performance of NIHSS |
Other biomarkers | ||||||
Haapaniem, 2000 | Case control | AIS | 101 AIS, 101 CTRL | ET-1 | Plasma | No difference in ET-1 levels between stroke and controls |
Lampl, 1997 | Pro | AIS within 18 h from onset | 26 | ET-1 | CSF, Plasma | CSF ET-1 correlated with volume of the lesion and higher in cortical infarcts compared to subcortical infarcts. Plasma ET-1 was not elevated |
Chiquete, 2012 | Pro | AIS | 463 | UA | Serum | UA ≤ 4.5 mg/dL at hospital admission was associated with very good 30 day outcome (OR 1.76 [1.05–2.95]; 81.1 % NPV) |
Matsumoto, 2012 | Retro | AIS from non-valvular AF within 48 h of onset | 124 | d-dimer | Plasma | d-dimer level at hospital admission is independently associated with infarct volume Highest d-dimer tertile group had worse outcome compared to middle and lowest tertiles |
AF atrial fibrillation, NPV negative predictive value, PPV positive predictive value, Pro prospective observational, RCT randomized controlled trial, Retro retrospective, CTRL control subjects, NIHSS NIH stroke scale, OR odds ratio